Skip to content
Screener

OptimizeRx OPRX Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$26.1MMiss by $4.8M
EPS$0.20Beat by $0.17
Revenue estimate$30.9M
EPS estimate$0.03

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate$0.19

Financials

Q3 2025

Income statement

See full
Revenue$26.1M+22.3%
Gross profit$17.5M+30.3%
Operating income$2.1M+124%
Net income$779.0K+109%
EPS (diluted)$0.04+108%

Balance sheet

See full
Cash & equivalents$19.5M+21.0%
Total debt$28.6M-19.9%
Total equity$122.3M+6.8%
Total assets$170.3M+3.1%

Cash flow

See full
Operating cash flow$3.2M+78.8%
CapEx$10.0K-44.4%
Free cash flow$3.2M+80.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$380.58M+169%
Enterprise value$389.67M+142%
P/E11,193.6×—
P/S3.5×+0.7×

Profitability

See full
Gross margin65.3%+30.1pp
Net margin0%0.0pp
FCF margin10.7%+8.7pp

Returns & leverage

See full
Return on equity0%0.0pp
Debt / equity0.2×-0.1×
Current ratio3×-0.2×

Segments

By product

See full
Solutions Sold On A Commissions Bases, Agent Revenue Recognized On A Net Basis$2.9M+4.4%

FAQ

When did OptimizeRx report Q3 2025 earnings?
OptimizeRx (OPRX) reported Q3 2025 earnings on November 6, 2025 after market close.
What were OptimizeRx's Q3 2025 revenue and EPS?
OptimizeRx reported revenue of $26.1M and eps of $0.20 for Q3 2025.
Did OptimizeRx beat estimates in Q3 2025?
Revenue missed the consensus estimate of $30.9M by $4.8M. EPS beat the consensus estimate of $0.03 by $0.17.
How did OptimizeRx's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.3% from $21.3M a year earlier and eps grew 66.7% from $0.12.
Where can I find OptimizeRx's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001448431-25-000018) and the 10-Q periodic report (0001448431-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.